 |
| Morphotek |
 |
|
 |
Morphotek, Inc. is a biopharmaceutical company focused on the discovery and development of therapeutic monoclonal antibodies (mAb) for the treatment of cancer, inflammatory and infectious diseases. Morphotek develops these antibodies through the use of its proprietary human antibody technologies, Human MORPHODOMA® and Libradoma™. The company’s lead compound, Farletuzumab (Morab 003) is currently being studied in platinum sensitive ovarian cancer (ph.3) and platinum resistant ovarian cancer (ph.2). For further information, please visit www.ovarianstudies.com. As a wholly owned subsidiary of Eisai, Ltd., Morphotek has retained an independent workplace while benefiting from the ability to collaborate and actively exchange ideas with Eisai scientists in laboratories around the world. Morphotek’s therapeutic antibodies and proprietary discovery technologies, combined with Eisai’s research and commercial infrastructure, will help Eisai meet its human health care goal of satisfying unmet medical needs and increasing benefits to cancer patients around the world. We welcome all inquiries regarding Morphotek via the website www.morphotek.com. |
|
|
|
|
|
|
